Amneal Pharmaceuticals Inc (NYSE:AMRX) Shares Sold by Citigroup Inc.

Citigroup Inc. cut its stake in shares of Amneal Pharmaceuticals Inc (NYSE:AMRX) by 64.8% during the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 12,180 shares of the company’s stock after selling 22,394 shares during the quarter. Citigroup Inc.’s holdings in Amneal Pharmaceuticals were worth $165,000 as of its most recent filing with the Securities and Exchange Commission.

Other institutional investors also recently made changes to their positions in the company. Zurcher Kantonalbank Zurich Cantonalbank lifted its position in shares of Amneal Pharmaceuticals by 28.3% during the 4th quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 6,700 shares of the company’s stock valued at $91,000 after acquiring an additional 1,477 shares during the period. JPMorgan Chase & Co. raised its holdings in Amneal Pharmaceuticals by 12.8% during the third quarter. JPMorgan Chase & Co. now owns 24,155 shares of the company’s stock worth $536,000 after buying an additional 2,739 shares during the last quarter. Hsbc Holdings PLC raised its holdings in shares of Amneal Pharmaceuticals by 14.9% in the third quarter. Hsbc Holdings PLC now owns 28,613 shares of the company’s stock valued at $635,000 after purchasing an additional 3,706 shares during the last quarter. DekaBank Deutsche Girozentrale purchased a new stake in shares of Amneal Pharmaceuticals in the third quarter valued at about $101,000. Finally, Quantamental Technologies LLC purchased a new stake in shares of Amneal Pharmaceuticals in the fourth quarter valued at about $68,000. 38.88% of the stock is currently owned by institutional investors.

Several equities analysts recently weighed in on AMRX shares. Cantor Fitzgerald restated a “buy” rating and set a $35.00 price target on shares of Amneal Pharmaceuticals in a research report on Thursday, February 28th. SunTrust Banks initiated coverage on shares of Amneal Pharmaceuticals in a research report on Tuesday, March 19th. They set a “buy” rating and a $16.00 target price for the company. Svb Leerink downgraded shares of Amneal Pharmaceuticals from an “outperform” rating to a “market perform” rating and lowered their price target for the stock from $16.00 to $12.00 in a report on Friday, March 8th. Leerink Swann downgraded shares of Amneal Pharmaceuticals to a “market perform” rating in a report on Friday, March 8th. Finally, Zacks Investment Research downgraded shares of Amneal Pharmaceuticals from a “hold” rating to a “sell” rating in a research note on Monday, January 14th. Two research analysts have rated the stock with a sell rating, seven have given a hold rating and four have given a buy rating to the company’s stock. The stock presently has a consensus rating of “Hold” and a consensus target price of $20.80.

Shares of AMRX stock opened at $12.43 on Friday. Amneal Pharmaceuticals Inc has a 12 month low of $11.63 and a 12 month high of $24.48. The firm has a market cap of $3.72 billion, a PE ratio of 13.08, a price-to-earnings-growth ratio of 0.59 and a beta of 1.38. The company has a current ratio of 2.32, a quick ratio of 1.50 and a debt-to-equity ratio of 2.98.

Amneal Pharmaceuticals (NYSE:AMRX) last posted its quarterly earnings results on Thursday, February 28th. The company reported $0.32 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.26 by $0.06. The firm had revenue of $497.53 million during the quarter, compared to analyst estimates of $478.06 million. Amneal Pharmaceuticals had a return on equity of 25.73% and a net margin of 1.84%. As a group, analysts expect that Amneal Pharmaceuticals Inc will post 0.97 earnings per share for the current year.

In related news, Director Peter R. Terreri sold 23,345 shares of the business’s stock in a transaction that occurred on Wednesday, March 6th. The stock was sold at an average price of $12.39, for a total transaction of $289,244.55. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, insider Paul Bisaro acquired 17,000 shares of the business’s stock in a transaction that occurred on Tuesday, March 12th. The shares were bought at an average price of $11.97 per share, with a total value of $203,490.00. The disclosure for this purchase can be found here. 26.34% of the stock is currently owned by insiders.

COPYRIGHT VIOLATION WARNING: “Amneal Pharmaceuticals Inc (NYSE:AMRX) Shares Sold by Citigroup Inc.” was first published by Baseball Daily News and is the sole property of of Baseball Daily News. If you are reading this piece of content on another website, it was stolen and reposted in violation of U.S. & international trademark & copyright legislation. The legal version of this piece of content can be read at https://www.baseballdailydigest.com/news/2019/04/27/citigroup-inc-has-165000-stake-in-amneal-pharmaceuticals-inc-amrx.html.

About Amneal Pharmaceuticals

Amneal Pharmaceuticals, Inc, together with its subsidiaries, develops, licenses, manufactures, markets, and distributes generic and specialty pharmaceutical products for various dosage forms and therapeutic areas. It operates through two segments, Generics and Specialty. The Generics segment develops, manufactures, and commercializes complex oral solids, injectables, ophthalmics, liquids, topicals, softgels, inhalation products, and transdermals across a range of therapeutic categories.

Further Reading: What are momentum indicators and what do they show?

Institutional Ownership by Quarter for Amneal Pharmaceuticals (NYSE:AMRX)

Receive News & Ratings for Amneal Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amneal Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.